IP Library Granted Patent US 10,568,859
Granted Patent B2
US 10,568,859 · App. 12/711,337 · Granted Feb 25, 2020

Topical foam composition

Inventor: Leon Loupenok (Rowville, AU)
Assignee: MAYNE PHARMA LLC
A61K31/203A61K9/0014A61K9/1075A61K9/122A61K31/00A61K31/192A61K31/4436A61K45/06Y10S514/938Y10S514/939Y10S514/941Y10S514/945
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,568,859
App. No.
12/711,337
Granted
Feb 25, 2020
Kind
B2
Abstract

The present invention relates to a novel oil in water emulsion aerosol foam composition containing an active agent for the treatment of various chronic and acute skin conditions, particularly acne and psoriasis; and processes for preparing the emulsion aerosol foam compositions. In particular, the present invention relates to oil in water emulsion aerosol foam compositions containing a retinoid in the oil phase.

Claims (29)

1. An oil in water emulsion aerosol foam composition comprising an oil phase and a water phase, said composition comprising:

i) tazarotene,

ii) water in an amount from about 65% to about 90% by weight,

iii) an oil present in an amount from about 1% to about 9% by weight, wherein the oil is selected from the group consisting of azulene, chamazulene, isoparaffin, linear alpha olefins, cyclohexlidenediphenyl methane, didecene, diethylhexylcydohexane, eicosane, isododecane, isoeicosane, isohexadecane, longifolene, mineral oil, light mineral oil, paraffin, pentahydrosqualene, petrolatum, squalane, squalene, tetradecene, and mixtures thereof,

iv) an oil miscible organic solvent selected from the group consisting of diisopropyl adipate, isopropyl myristate, octyl dodecanol, caprylic/capric triglycerides, and mixtures thereof,

v) a surfactant component comprising from about 1% to about 8% by weight of a surfactant selected from the group consisting of ceteareth-12, oleth-10, and a mixture thereof, and

vi) a propellant selected from the group consisting of hydrocarbon propellants and mixtures thereof,

wherein the tazarotene is solubilized in the oil phase of the composition, wherein the particle size of the oil phase is less than about 1000 nm, and wherein all percentages are based on the total weight of the composition.

2. The aerosol foam composition according to claim 1 , wherein the composition comprises water in an amount from about 70% to about 85% by weight.

3. The aerosol foam composition according to claim 2 , wherein the oil is light mineral oil.

4. The aerosol foam composition according to claim 3 , wherein the light mineral oil is present in an amount from about 3% to about 8% by weight.

5. The aerosol foam composition according to claim 1 , wherein the oil miscible organic solvent is diisopropyl adipate.

6. The aerosol foam composition according to claim 4 , wherein the surfactant comprises ceteareth-12.

7. The aerosol foam composition according to claim 6 , wherein the surfactant is present in amount from about 2% to about 6% by weight.

8. An oil in water emulsion aerosol foam composition comprising an oil phase and a water phase, said composition comprising:

i) tazarotene;

ii) water in an amount from about 70% to about 85% by weight;

iii) an oil present in an amount from about 3% to about 8% by weight, wherein the oil is light mineral oil;

iv) an oil miscible organic solvent present in an amount from about 3% to about 15% by weight, wherein the oil miscible organic solvent is diisopropyl adipate;

v) a surfactant component comprising from about 2% to about 6% by weight of a hydrophilic ethoxylated fatty alcohol ether, wherein the hydrophilic ethoxylated fatty alcohol ether is ceteareth-12

vi) a propellant selected from the group consisting of hydrocarbon propellants and mixtures thereof,

wherein the tazarotene is solubilized in the oil phase of the composition, wherein the particle size of the oil phase is less than about 1000 nm, and wherein all percentages are based on the total weight of the composition.

9. A method of treating a skin disease, disorder or condition, comprising administering to the skin of a patient requiring such treatment an effective amount of a composition according to claim 8 .

10. The aerosol foam composition according to claim 8 , further comprising a preservative that is a combination of sorbic acid and a salt thereof.

11. The aerosol foam composition according to claim 8 , wherein the mean particle size of the oil phase is about 100 nm.

12. The aerosol foam composition according to claim 8 , wherein the surfactant component consists of ceteareth-12.

13. The aerosol foam composition according to claim 1 , wherein the surfactant component consists of ceteareth-12, oleth-10, or a mixture thereof.

14. The aerosol foam composition according to claim 1 , wherein the composition is chemically and physically stable regardless of whether any other surfactant component besides ceteareth-12, oleth-10, or a mixture thereof also is present.

15. The aerosol foam composition according to claim 13 , wherein the surfactant component consists of ceteareth-12, or a mixture of ceteareth-12 and oleth-10.

Assignments (4)
RELEASE OF SECURITY INTEREST Recorded Jun 3, 2024
From: WESTPAC ADMINISTRATION PTY. LIMITED ACN 008 617 203
To: MAYNE PHARMA LLC
Reel/Frame 067598/0194 →
SECURITY INTEREST Recorded Jul 25, 2022
From: MAYNE PHARMA LLC
To: WESTPAC ADMINISTRATION PTY. LIMITED
Reel/Frame 060602/0385 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 6, 2016
From: STIEFEL RESEARCH AUSTRALIA PTY LTD
To: MAYNE PHARMA LLC
Reel/Frame 039959/0207 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 14, 2010
From: LOUPENOK, LEON
To: STIEFEL RESEARCH AUSTRALIA PTY LTD
Reel/Frame 024231/0134 →
Continuity (2)
Provisional Application 61202403 · Feb 25, 2009
Related Publication 20100221194A1 · Sep 2, 2010
Cited By (1)
US 12,447,161